FDA approves Shire's triple-bead ADHD therapy

FDA approved Mydayis (SHP465) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat ADHD in patients ages 13 and older. The product consists of 3-component, extended release, single-entity mixed amphetamine...